Medicinal chemistry of non-peptidomimetic dipeptidyl peptidase IV (DPP IV) inhibitors for treatment of Type-2 diabetes mellitus: Insights on recent development

Nowadays, dipeptidyl peptidase -IV (DPP-IV) is emerging as a hopeful drug target for treating Type 2 diabetic mellitus (T2DM). Currently marketed DPP-IV inhibitors work by lowering the blood glucose level in T2DM without any common side effects including hypoglycaemia, weight gain and gastrointestinal disturbances. Hence, DPP-IV inhibitors pleased the attention of researchers and medicinal chemists. Especially, non-peptidomimetic DPP-IV inhibitors after the launch of sitagliptin in 2006. In recent years, researchers have taken delightful medicinal effort s to discover promising DPP-IV inhibitors without complexity. This constructive review focuses on molecular insights, recent medicinal aspects in design and discovery with special emphasis on structure activity relationships of potential DPP-IV inhibitors in recent years.(c) 2023 Published by Elsevier B.V.